Table 2.
Subject CYP2C19 metabolic status versus success of clarithromycin triple therapy
| Phenotype | Genotype | N | Eradicated | % Success |
|---|---|---|---|---|
| Normal |
*1/*1 WT/WT |
20 | 16 | 80.0% |
| Rapid |
*1/*17 *17/WT |
11 | 2 | 18.2% |
| P value | 0.0017 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.